Haldol

Haldol is the brand name for the antipsychotic medication haloperidol, supplied in oral dosage forms and marketed in the European Union. It belongs to the butyrophenone class and works as a dopamine D2 receptor antagonist. Haldol is prescribed by healthcare professionals for several psychiatric conditions and is available only with a prescription.

Haldol is indicated for the management of several psychiatric disorders where dopamine dysregulation is a factor.

- Treatment of schizophrenia, including maintenance therapy. - Management of acute psychotic episodes. - Control of manic episodes associated with bipolar disorder. - Reduction of motor and vocal tics in Tourette syndrome. - Adjunctive therapy for severe agitation in various mental health settings.

Side effects of haloperidol can vary in frequency and severity, and patients should be monitored regularly.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and constipation. - Blurred vision. - Weight gain. - Orthostatic hypotension.

Serious: - Tardive dyskinesia (involuntary movements). - Neuroleptic malignant syndrome (fever, muscle rigidity). - Severe cardiac arrhythmias (QT prolongation). - Hyperprolactinemia leading to hormonal disturbances. - Agranulocytosis (low white blood cell count).

When prescribing or taking Haldol, several safety considerations are important.

- Assess cardiovascular risk, especially for QT prolongation. - Monitor for signs of extrapyramidal symptoms and tardive dyskinesia. - Use caution in patients with a history of seizures or neurological disorders. - Evaluate liver and kidney function before initiating therapy. - Discuss pregnancy and breastfeeding considerations with a healthcare provider. - Adjust dose in elderly patients to reduce fall risk. - Review any history of substance abuse or medication non‑adherence.

Haloperidol can interact with other medications, affecting its efficacy and safety.

Avoid: - Other dopamine antagonists or antipsychotics that increase extrapyramidal risk. - Medications that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors that may raise haloperidol levels.

Use with caution: - CNS depressants such as benzodiazepines or opioids, which may enhance sedation. - Anticholinergic agents that can mask extrapyramidal symptoms. - Antihypertensive drugs, as haloperidol may cause orthostatic hypotension. - CYP2D6 substrates, which could be affected by metabolic competition.